Discontinue use if GI haemorrhage or ulceration occur; at 1st sign of rash, mucosal lesions or any other signs of hypersensitivity reactions. History of bronchial asthma, chronic rhinitis, allergic disease; serious GI events & other risk factors associated w/ PUD eg, alcoholism, smoking, corticosteroid therapy. Uncontrolled HTN, heart failure (NYHA II), established ischemic heart disease, peripheral arterial disease &/or cerebrovascular disease; fluid retention w/ oedema &/or arterial HTN, cardiac impairment or other conditions predisposing to fluid retention; severe dehydration or post-op vol shifts; aseptic meningitis, SLE, collagenosis. May mask symptoms of infections. Perform ophth exam in patients w/ visual disturbances. May produce increased LFT results. Avoid high-dose use (2,400 mg daily). Long-term treatment of patients w/ risk factors for CV events eg, HTN, hyperlipidemia, DM, smoking. Patients on controlled Na diet. Not to be taken by patients w/ fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency. Avoid combination w/ NSAIDs including selective COX-2 inhibitors. Concomitant use w/ medicines increasing risk of ulceration or haemorrhage eg, oral corticosteroids, anticoagulants (eg, warfarin), SSRIs, platelet aggregation inhibitors (eg, ASA); diuretics, ACE inhibitors. Renal insufficiency, papillary necrosis & toxicity. Hepatic insufficiency. Not recommended in women of childbearing potential, during 1st & 2nd trimesters of pregnancy. Not to be used during lactation. Elderly or debilitated patients.
Sign Out
